Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

Lund, Sweden, September 10, 2013 – Camurus announced today that Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 ...

Syringe and Vials To date, the Company has not received any reports of adverse reactions related to this recall. Mylan Institutional LLC, a Viatris Company, has voluntarily recalled 1 lot of ...

Presence of robust pipeline of drugs in clinical trials is the prime factor fueling market growth. For instance, in 2016, Mario Negri Institute for pharmacological research completed phase 2 clinical ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an oral form of the somatostatin analogue octreotide as a long-term maintenance therapy for ...

Viatris Inc's (NASDAQ: VTRS) Mylan is voluntarily recalling one lot of Octreotide Acetate Injection, 500 mcg/mL, packaged in a carton of ten 1mL syringes due to a product complaint of the presence of ...